Healthcare providers need to agree on a definition of value, but that discussion must include the voice of the patient, according to Eleanor Perfetto, PhD, senior vice president of strategic initiatives for the National Health Council. Patient input is especially important when the conversation results in a decision that could affect access to care.
Healthcare providers need to agree on a definition of value, but that discussion must include the voice of the patient, according to Eleanor Perfetto, PhD, senior vice president of strategic initiatives for the National Health Council. Patient input is especially important when the conversation results in a decision that could affect access to care.
Transcript (slightly modified)
Why do you think it’s so difficult to determine value and what tools are available to help?
Now value is a word that’s really hard to define, I think we all have an idea in our mind what we think value means, but when you’re asked to give a definition of “what is value in healthcare?” it’s really hard to pinpoint. And I think that’s one of the things we’re struggling about this year with so much discussion about value. We need to make sure that we’re all on the same page with our definition, and we haven’t gotten there yet.
For patients, what’s really important is that when there’s a discussion going on about value, and what’s value in healthcare, and that discussion produces a decision that could mean access or lack of access to the patient community, patients want to be involved in that discussion. They want to be at the table. They want to really know that their voice has been heard in what they consider to be value.
The definition of value can be different for every disease and condition, and so that patient voice is really important.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More